💨 Abstract

A study in Virginia found that nearly 25% of newly-diagnosed advanced lung cancer patients did not receive crucial biomarker testing for the EGFR mutation. This testing is vital for determining appropriate treatment, potentially avoiding chemotherapy and improving patient outcomes. Delays in testing due to next-generation sequencing can cause anxiety and treatment delays. Experts emphasize the importance of early testing to ensure the best treatment and reduce side effects.

Courtesy: Neal Augenstein